drugset / Trial / NCT05429593

A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet

NCT05429593

Phase 1 Completed 152 enrolled Novo Nordisk A/S
RandomizedCrossoverOpen-labelTreatment

Summary

This study will test how the active substances semaglutide and dapagliflozin act in the body (in terms of their levels in the blood), when they are taken in the form of a combination preparation (a tablet with a fixed dose combination) compared to when oral semaglutide and dapagliflozin are given alone.The study will consist of 2 parts. Part 1 will compare semaglutide to the fixed dose combination tablet (semaglutide/dapagliflozin) and part 2 will compare dapagliflozin to the fixed dose combination tablet (semaglutide/dapagliflozin). Participants will take part in either part 1 or part 2.

Timeline

Start
2022-06-22
Primary completion
2023-03-10
Completion
2023-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule Oral
Subject Semaglutide Peptide Oral

Indications

No indication recorded.